Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01328522 · ClinicalTrials.gov registry record · Phase 1

Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients

A Phase 1 study of Rheumatoid Arthritis, sponsored by Sanofi.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target
4
Study locations

NCT01328522: Completed Phase 1 study of Rheumatoid Arthritis, sponsored by Sanofi.

NCT01328522 is a Phase 1 study of Rheumatoid Arthritis that has completed, run by Sanofi. The registered enrollment target is 32 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01328522, a Phase 1 study of Rheumatoid Arthritis, has completed, sponsored by Sanofi.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target
4
Study locations

Study Summary

Primary Objective: Assess the comparative safety and tolerability of two SAR153191 (REGN88) drug products after a single dose administration in rheumatoid arthritis patients. Secondary Objective: Assess the comparative pharmacokinetic profiles of the two SAR153191 (REGN88) drug products after a single dose administration in rheumatoid arthritis patients.

Conditions Studied

Rheumatoid Arthritis

Interventions

  • DRUG SAR153191 (REGN88)

Study Locations (4)

California

  • Investigational Site Number 840003 - Beverly Hills

Florida

  • Investigational Site Number 840001 - Ocala

Pennsylvania

  • Investigational Site Number 840004 - Duncansville

Texas

  • Investigational Site Number 840002 - Dallas

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2011-05
Est. Completion 2011-09
Phase Phase 1
Sanofi

713 total trials

What the finished NCT01328522 record still lists

NCT01328522 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which SAR153191 (REGN88) is the first listed.

NCT01328522 reports a single indexed study location in California, Florida, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01328522 about?

NCT01328522 is a clinical study titled "Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients". Primary Objective: Assess the comparative safety and tolerability of two SAR153191 (REGN88) drug products after a single dose administration in rheumatoid arthritis patients. Secondary Objective: Assess the comparative pharmacokinetic profiles of the two SAR153191 (REGN88) drug products after a s...

What is the current status of trial NCT01328522?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2011-05. Estimated completion is 2011-09.

What conditions does trial NCT01328522 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT01328522?

The interventions under investigation include: SAR153191 (REGN88) (DRUG).

Who is sponsoring clinical trial NCT01328522?

This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01328522 being conducted?

This trial has 4 study locations across California, Florida, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01328522's enrollment target sits among peer trials

32 156th of 197 higher than 40 of 197 other Rheumatoid Arthritis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01328522, the US trial registry maintained by the National Library of Medicine. NCT01328522 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.